Company profile
MOLECULIN BIOTECH, INC.
NASDAQ:MBRXBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| MOL-4239 | phase2 | — | 2 | no active trials |
| WP-1122 | phase1 | — | 1 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06788756 | phase2_3 | recruiting | 2025-03-12 | 2029-08-01 | Moleculin Biotech, Inc. | L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML |
| NCT01826201 | phase2 | completed | 2013-03-01 | 2013-08-01 | Moleculin, LLC | Paired Psoriasis Lesion, Comparative, Study to Evaluate MOL4239 in Psoriasis |
| NCT03315039 | phase1_2 | completed | 2018-03-28 | 2020-01-14 | Moleculin Biotech, Inc. | Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML) |
| NCT03388749 | phase1_2 | completed | 2018-12-17 | 2022-02-08 | Moleculin Biotech, Inc. | Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML) |
| NCT04887298 | phase1_2 | completed | 2021-06-05 | 2022-09-29 | Moleculin Biotech, Inc. | Study of Liposomal Annamycin for the Treatment of Subjects with Soft-Tissue Sarcomas (STS) with Pulmonary Metastases |
FDA applications (0)
No records yet.